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Abstract
A recent meta-analysis of prospective cohort studies has not found an association between dietary saturated fat intake and CHD incidence.
This funnelled the discussion about the importance of the recommendation to lower the intake of saturated fat for the prevention of CHD.
At the same time a document of the European Food Safety Authority has suggested that specific quantitative recommendations are not
needed for individual fatty acids but that more general statements can suffice. In this review, we discuss methodological aspects of the
absence of association between SFA intake and CHD incidence in prospective cohort studies. We also summarise the results of the con-
trolled dietary experiments on blood lipids and on CHD incidence in which saturated fat was replaced by either cis-unsaturated fat or
carbohydrates. Finally, we propose a nutritionally adequate diet with an optimal fatty acid composition for the prevention of CHD in
the context of dietary patterns. Such diets are characterised by a low intake of saturated fat, and as low as possible intake of trans-fat
and fulfil the requirements for the intake of n-6 and n-3 fatty acids. No recommendation is needed for the intake of cis-MUFA.
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The recommendation to lower saturated fat in the diet for the
prevention of CHD has recently been challenged(1). In their
meta-analysis of prospective cohort studies, Siri-Tarino et al.(2)
found that dietary SFA were not associated with an increased
risk of CHD. The same authors(2) argued that substitution of
saturated fat by carbohydrates, especially refined carbohydrates,
may actually increase the risk of CHD. They attributed this to
differential effects of dietary saturated fats and carbohydrates
on concentrations of larger and smaller LDL particles and con-
cluded that replacement of saturated fats by carbohydrates
may increase CHD risk through atherogenic dyslipidemia(2).
Besides the discussion on the controversial role of dietary
saturated fat, the optimal amount of total fat and individual fatty
acids for CHD prevention is also debated in the scientific commu-
nity. Do we need specific quantitative recommendations for total
fat and individual fatty acids, or doquantitative recommendations
for some fatty acids and general statements for others suffice?
The latter approach was taken in the Dietary Reference Values
for fats of the European Food Safety Authority (EFSA)(3).
Examples of the EFSA recommendations are ‘the lower the
better’ for saturated fat, no recommendation for cis-MUFA
and ‘at least 250mg/d’ for the n-3 fatty acids EPA and DHA.
In this review, we challenge the interpretation of Siri-Tarino
et al. about the absence of association between saturated
fat and risk of CHD in prospective cohort studies, discuss
the effect on CHD incidence of replacement of saturated
fat by cis-unsaturated fat v. carbohydrates in controlled dietary
experiments, and provide recommendations for fatty acids
and dietary patterns for CHD prevention.
Lack of association between dietary saturated fat and
CHD risk
The recently published meta-analysis of sixteen prospective
cohort studies by Siri-Tarino et al.(1) has not provided evi-
dence that a high intake of saturated fat is associated with
an increased risk of CHD. This meta-analysis included
214 182 subjects who were followed up for 5–23 years and
developed 8644 cases of CHD. The median or mean of
saturated fat intake in these studies varied between 12 and
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20 % of energy. The pooled relative risk comparing extreme
quantiles of saturated fat was 1·07 (95 % CI 0·96, 1·19;
P¼0·22) for CHD. This finding is discordant with the classic
diet–heart hypothesis that a high saturated fat intake increases
the risk of CHD, mediated by raised serum cholesterol.
In his editorial accompanying the article by Siri-Tarino et al.,
Stamler(4) argues that the diet–heart hypothesis is supported
by a vast array of concordant evidence from multidisciplinary
research. A major issue in this context is the accuracy of
dietary data in epidemiological studies on saturated fat and
CHD. Balogh et al.(5) had already shown many years ago
that twenty-two randomly collected 24-h dietary recalls are
required to estimate the true individual mean intake within
^20 %, while most studies have only one recall or a food
frequency measure of saturated fat intake available. Therefore,
the weak associations found may be explained by unreliability
of this aspect of dietary information in observational studies.
We discuss in more detail the methodological aspects related
to dietary saturated fat, serum cholesterol and CHD.
Parallel to the lack of association between saturated fat
intake and CHD risk, as shown in the meta-analysis, is the
lack of association between dietary saturated fat and serum
cholesterol in cross-sectional analyses of the Framingham,
Tecumseh and Zutphen studies(6–8). Keys(9) explained the
lack of an association between dietary saturated fat and
serum cholesterol in cross-sectional studies by the large day-
to-day variation within individuals in both saturated fat
intake and serum cholesterol. He showed that the intra-
individual variance of the SFA palmitic acid was more than
twice as large as the inter-individual variance, based on two
measurements. He also found that in healthy adults on an
ostensibly constant diet, the average intra-individual standard
deviation of serum cholesterol was approximately 200 mg/l
(20 mg/dl), about half the total standard deviation(9).
The mathematical aspects of the zero or low-level corre-
lation between dietary saturated fat and serum cholesterol
were dealt with in a paper by Jacobs et al.(10). Even with a
fixed diet, serum cholesterol will vary due to differences in
blood sampling, chemical analysis and variation in cholesterol
levels unrelated to diet. Besides the variability in serum
cholesterol there is also substantial variability in estimating
dietary fatty acids. Jacobs et al. described the following
sources of variation: (1) errors in identifying foods in food
tables, (2) discrepancy between food table values and the
true composition in foods eaten, (3) errors in estimating quan-
tities of food eaten, (4) errors in remembering what was eaten
and (5) differences in the food pattern of the observation
period and that of the previous 2–4 weeks. These sources
of error in both the dietary exposure and the effect measure
will attenuate the correlation between dietary saturated fat
and serum cholesterol. The attenuation of the true correlation
is determined by the ratio of the variance between intra- and
inter-individual variations. The larger the intra-individual vari-
ation, the larger the error term and the smaller the observed
correlation.
It is therefore not a surprise that zero correlations were
observed between dietary saturated fat and serum cholesterol
in cross-sectional analyses. Jacobs et al.(10) stated in their
article ‘A corollary of the mathematical model here presented
is that a correlation close to zero would likely be observed
between diet e.g. dietary saturated fat and coronary heart dis-
ease incidence.’ The results of the meta-analysis by Siri-Tarino
et al.(1) are an illustration of their prophecy. Jacobs et al.(10)
concluded their article by saying that ‘An appropriate design
for demonstrating or refuting diet and coronary heart disease
incidence is a dietary experiment.’
Effect of different SFA on total and HDL-cholesterol
The classical controlled dietary experiments carried out before
1970 showed that replacing saturated fat, generally by starch
or sucrose, decreased serum cholesterol, while replacing
starch or sucrose by polyunsaturated fat also decreased
serum cholesterol(11,12). The serum cholesterol-raising effect
of saturated fat was twice as strong as the decreasing effect
of polyunsaturated fat. Controlled dietary experiments carried
out after 1970 showed a somewhat smaller serum cholesterol-
raising effect when carbohydrate was replaced by saturated
fat and only half of the serum cholesterol-decreasing effect
after replacement of carbohydrate by polyunsaturated fat(13).
This was recently confirmed by the large multi-centre Read-
ing University, Imperial College London, Surrey University,
MRC Human Nutrition Research Cambridge and King’s
College London (RISCK) trial(14).
A recent meta-analysis of controlled feeding experiments
showed that SFA with twelve, fourteen and sixteen carbon
atoms in contrast to the one with eighteen carbon atoms
increased LDL-cholesterol when they isoenergetically replaced
carbohydrate(15). All four SFA raised HDL-cholesterol, but
the HDL-cholesterol-raising effect was greater as the chain
length decreased. Overall, the total:HDL cholesterol ratio is
not affected by the SFA with fourteen, sixteen and eighteen
carbon atoms, but is significantly reduced when the SFA
with twelve carbon atoms replaces carbohydrate. However,
replacement of SFA with 12–18 carbon atoms by cis-MUFA-
and -PUFA leads to lowering of total and LDL-cholesterol,
while only slightly lowering HDL-cholesterol, and thus
improving the total:HDL cholesterol ratio and CHD risk(16).
Besides the effect of the chain length there may also be
an effect of the source (e.g. animal v. plant origin and natural
v. interesterified) of saturated fat on total and HDL-cholesterol.
This was reviewed by Hayes & Pronczuk(17). They noted that
typical diets provide 2–4 % of energy as stearic acid (18 : 0)
from natural fats. When a hardened fat is needed (replacing
food applications that until recently used trans-fats), an unmo-
dified saturated fat, for example from a palm or coconut pro-
duct, was seen as preferable to interesterified fat(17). At 2–4 %
interesterified 18 : 0, effects on total and HDL-cholesterol and
on glucose and insulin metabolism, immune function and
liver enzymes are small. Detection of adverse effects starts at
only approximately 7–8 % of energy or higher, although, simi-
lar to trans-fat, adverse effects of lower levels of interesterified
fatty acids on other body systems could not be ruled out(17).
We agree with Hayes & Pronczuk(17) that interesterified fatty
acids should be used sparingly until more evidence about
their health effects has become available.

















Replacement of saturated fat by cis-unsaturated fat or
carbohydrates and CHD risk in controlled dietary
experiments
Different strategies are available for replacing the energy lost
when lowering saturated fat intake. Among these strategies,
saturated fat can be replaced by either cis-unsaturated fatty
acids or carbohydrates. In most controlled dietary experiments
of CHD risk, saturated fats were replaced by polyunsaturated
vegetable oils(18). The PUFA studied were mainly n-6 fatty
acids (linoleic acid) and small amounts of the n-3 fatty acid
a-linolenic acid (ALA) in some cases, e.g. when soyabean
oil was used. Meta-analyses of short-term controlled dietary
experiments lasting generally 4–6 weeks showed that these
PUFA favourably influence the LDL:HDL cholesterol
ratio(13,16). This ratio is a better predictor of CHD risk than
total cholesterol or the individual lipoprotein fractions(13).
Between 1968 and 1992 eight controlled dietary experiments
of more than 1-year duration with hard coronary end points
were reported(19). In these trials, control diets were charac-
terised by both a high total fat (35–45 % of energy) and a
high saturated fat content (approximately 20 % of energy).
The average polyunsaturated fat consumption was 15 % of
energy in the intervention groups and 5 % of energy in the
control groups. Replacement of saturated by polyunsaturated
fat changed the polyunsaturated:saturated (P:S) ratio from
approximately 0·2 to 2. The overall pooled risk reduction in
CHD incidence was 19 % corresponding to 10 % reduced risk
per 5 % energy of increased polyunsaturated fat intake. Study
duration was an independent determinant of risk reduction,
with studies of longer duration showing greater benefits(19).
Ramsden et al.(20) concluded from the meta-analysis by
Mozaffarian et al.(19) that the effect of replacement of SFA by
PUFA on CHD incidence could not be exclusively ascribed
to an effect of n-6 PUFA. After an extensive literature search
and dietary data extraction they concluded that in only three
of the eight trials saturated fat was solely replaced by n-6
polyunsaturated fat and in the other five by a mixture of n-6
and n-3 fatty acids. In the latter trials, the CHD incidence
was reduced by 22 % when saturated fat was replaced by a
mixture of n-6 and n-3 PUFA. No effect was observed in the
other three trials, but the number of studies was too small to
draw conclusions. We agree with Ramsden et al.(20) that the
effect of replacement of saturated fat by polyunsaturated fat
on CHD incidence in the meta-analysis by Mozaffarian
et al.(19) should be ascribed to the combined effects of n-6
and n-3 PUFA. However, as Mozaffarian et al.(19) showed,
the effect on CHD incidence is in accord with the effect of
the change in fatty acids on the total:HDL cholesterol ratio.
Taking the results of these two meta-analyses together, we
conclude that the effect of replacement of saturated fat by a
mixture of n-6 and n-3 polyunsaturated fat can be ascribed
to an effect of blood lipids and to that of n-3 PUFA indepen-
dent of blood lipids, e.g. through prevention of ventricular
arrhythmias(21).
The alternative to replace energy from saturated fat
with carbohydrates is much more complex, because
‘carbohydrates’ actually encompass a huge range of foods
varying from high to low in micronutrients, phytochemicals
and fibre (fruits, vegetables, whole grains v. sugar and refined
grain). These two replacement strategies within the context
of ‘carbohydrates’ are not likely to have the same effect on
long-term risk. Only one controlled dietary experiment of
long-term CHD risk has been carried out using this strategy(22).
Therefore, we also report here the recently published results
of a Danish cohort study in which SFA in the statistical
model were substituted for carbohydrates with low glycaemic
index values (a marker of healthy carbohydrate-containing
foods). This was associated with a lower risk of myocardial
infarction(23). However, replacing SFA with carbohydrates
with high glycaemic index values (a marker of unhealthy
carbohydrate-containing foods) was associated with a higher
risk(23). In a large long-term controlled dietary experiment
carried out in 48 835 women aged 50–79 years, energy from
fat decreased by 8 % and carbohydrates increased by the
same percentage(22). This trial population had a low habitual
fibre intake (15 g/d) and the difference in fibre intake between
the high- and low-carbohydrate groups was 2·4 g/d. Over
8 years of follow-up, there was no effect of diet on the
total:HDL cholesterol ratio and CHD incidence(22). More
favourable results may be expected for low-fat diets with a
P:S ratio of at least 1 and a high fibre content (.50 g/d),
which would be rich in micronutrients and phytochemicals.
However, controlled trials that tested the effect of this type
of diet on CHD end points have not been carried out.
Given the paucity of controlled dietary experiments of CHD
risk using the carbohydrate replacement strategy, the influ-
ence of low-fat, high-carbohydrate diets on lowering serum
cholesterol is also of interest in this context. In a classic experi-
ment reported in 1981, Lewis et al.(24) compared diets low in
fat (27 % of energy with a P:S ratio of 1) and high in carbo-
hydrates (59 % of energy) that were either low (20 g/d) or
high (55 g/d) in fibre. The fibre-enriched diet contained
more fruit and vegetables and substituted whole-wheat
bread for white bread. The low-fat, high-fibre diet reduced
LDL-cholesterol by 35 % and HDL-cholesterol by 11 % while
the low-fat, low-fibre diet decreased LDL-cholesterol by 27 %
and HDL-cholesterol by 12 %. These results suggest that the
LDL:HDL cholesterol ratio is more favourably influenced by
the low-fat, high-fibre diet than by the low-fat, low-fibre
diet(24). These results were confirmed in a controlled dietary
experiment using a dietary portfolio of cholesterol-lowering
plant foods(25). The diet contained 29 % of energy from fat
with a P:S ratio of 1·6 and 77 g fibre/d.
A food-based dietary experiment carried out in a sub-study of
the Spanish PREvencio´n con DIeta MEDiterra´nea (PREDIMED)
Study is of further interest concerning fibre-rich diets, not
necessarily in a low total fat context(26). For this study, subjects
with at least two CHD risk factors were randomised into three
groups. The reference group was assigned to a low-fat diet
and the other two groups were allocated to a recommended
Mediterranean-style diet to which either 1 litre of extra virgin
olive oil per week or 30 g nuts/d was added. Both the olive oil
and the nut supplements were supplied to the participants by
the investigators. Both olive oil and nuts are rich in MUFA and
tree nuts also in n-6 and n-3 polyunsaturated fat. The diets

















with extra olive oil or nuts decreased LDL-cholesterol by 239
and 234 mg/l ( 2 3·9 and 2 3·4 mg/dl), and increased HDL-
cholesterol by 29 and 16 mg/l (2·9 and 1·6 mg/dl)(26). These
results were comparable to those obtained in controlled dietary
experiments(13,16).
In summary, replacement of saturated fat by polyunsatu-
rated fat decreases the LDL:HDL cholesterol ratio and reduces
the incidence of CHD. Replacement of saturated fat by
cis-MUFA decreases the LDL:HDL cholesterol ratio. Low-fat
diets high in carbohydrates but low in fibre do not change
the LDL:HDL cholesterol ratio. In contrast, low-fat diets with
a P:S ratio of at least 1 and high-fibre content do decrease
the LDL:HDL cholesterol ratio. Diets high in cis-MUFA and
low in fat with a P:S ratio of at least 1 and high fibre content
may reduce CHD risk, although this has not been proven
experimentally. This leads to the conclusion that different
diets could be designed to prevent CHD. This potential diver-
sity is crucial in engaging the diverse cultures and tastes
worldwide in cardiovascular prevention(18).
Optimal fatty acid composition and dietary patterns
for CHD prevention
The ultimate question to be answered is what the optimal fatty
acid composition of diets for CHD risk reduction could
be? Based on eight carefully controlled studies, Sacks &
Katan(18) concluded that trans-fatty acids had the worst
effect on blood lipids of all dietary fatty acids. cis-MUFA and
n-6 PUFA reduce the total:HDL cholesterol ratio, whereas
carbohydrates have a negligible effect on the ratio(16). How-
ever, if low-fat, high-carbohydrate diets with a P:S ratio of at
least 1 also had a high amount of fibre, a similar total:HDL
cholesterol ratio was obtained when saturated fat was
replaced by polyunsaturated fat(24,25). This suggests that for
optimal CHD risk reduction not only the fatty acid compo-
sition but also the fibre content, probably indicating a compo-
site of micronutrients and phytochemicals, is of importance.
Both saturated and trans-fatty acids not only have a detri-
mental effect on blood lipids but also increase CHD risk.
This was observed in controlled dietary experiments in
which saturated fat was replaced by vegetable oils rich in
mostly n-6 PUFA. These diets reduced CHD incidence and
the stronger the saturated fat reduction, the lower the CHD
incidence(19). When 5 % of energy from saturated fat was
replaced by a similar amount of mostly n-6 polyunsaturated
fat, CHD risk was reduced by 10 % (Table 1). Similar results
were obtained in a meta-analysis of pooled data of eleven
prospective cohort studies(27). Trans-fats increase the risk of
CHD even more strongly than saturated fats. These fatty
acids were introduced industrially in only a few products and
tend to have relatively low within-person variance in observa-
tional data. For trans-fatty acids data from only prospective
cohort studies are available. A meta-analysis of four studies
showed that a reduction in trans-fatty acid intake of 2 % of
energy is associated with a 24 % lower CHD risk (Table 1)(28).
n-3 Fatty acids also contribute to an optimal fatty acid
composition of the diet. The mother compound of these
fatty acids is ALA, a PUFA with eighteen carbon atoms and
three double bonds arising in plant oils, e.g. soyabean and
linseed oil. A meta-analysis of prospective cohort studies
showed that a high ALA intake compared to a low ALA
intake was associated with a lower, though not statistically
significant, risk of CHD mortality (relative risk 0·79; 95 % CI
0·60, 1·04)(29). Fish is an important source of the n-3 fatty
acids EPA and DHA. Meta-analyses showed that persons
who eat fish at least once a week have an approximately
15 % lower risk of fatal CHD(30). Meta-analyses of randomised
trials showed that an additional amount of EPA–DHA reduced
the risk of both fatal CHD and sudden cardiac death(31,32). In a
meta-analysis of both prospective cohort studies and trials,
Mozaffarian & Rimm(33) showed that an increase from 0 to
250 mg EPA and DHA per d was associated with a 36 %
lower CHD mortality risk (Table 1).
The results for the different fatty acids make clear the
large potential of an optimal fatty acid composition for
CHD prevention. Table 2 summarises broad recommendations
for an optimal fatty acid composition in the context of nutri-
tionally adequate diets(34,35). For CHD prevention, a recom-
mendation for total fat is not needed and may even be
counterproductive. High-fat diets (30–45 % of energy) with a
P:S ratio of more than 1 reduce the LDL:HDL cholesterol
levels and CHD incidence compared with diets high in satu-
rated fat with a P:S ratio of 0·2(16,19). Evidence is accumulating
that this may also be the case for a low-fat diet with a P:S ratio
of 1 and high-fibre content. However, low-fat, high-carbo-
hydrate diets with low fibre content, have an unfavourable
effect on blood lipoprotein fractions and therefore likely
also on CHD risk(2). Both SFA and, even more, trans-fatty
acids increase CHD risk. Therefore, we see merit in the
EFSA recommendation of an intake as low as possible for
Table 1. Summary of the results of prospective cohort studies and trials







5 % of energy of SFA replaced by PUFA 213(27) 210(19)
2 % of energy decrease in trans-MUFA 224(28) NA
Increase in EPA–DHA from 0 to 250 mg/d 236(33)* 236(33)*
NA, not available.
* Based on both cohort studies and trials.
Table 2. Summary of recommendations for fatty acid intake for adults*
Fatty acids
Prevents essential
fatty acid deficiency CHD prevention
Total fat No recommendation
SFA Low, as long as the diet
is nutritionally adequate
trans-Fatty acids As low as possible
cis-MUFA No recommendation
Linoleic acid .2·5 % of energy .5 % of energy
a-Linolenic acid .0·5 % of energy
EPA–DHA .250 mg/d
* Adapted from the scientific opinion on dietary reference values for fats from the Euro-
pean Food Safety Authority Panel on Dietetic Products, Nutrition, and Allergies(3).

















these fatty acids(3). However, this recommendation does not
mean that people must avoid all foods high in SFA, such as
chocolate, cheese, palm oil and coconut. We interpret the
EFSA recommendation as an incentive to consume a nutrition-
ally adequate diet with a low saturated fat content. To our
opinion, there is no minimal amount of saturated fat that
should be eaten. cis-MUFA compared with saturated and
trans-fatty acids have a favourable effect on the LDL:HDL
cholesterol ratio and possibly on CHD risk also. They are,
however, not essential and, therefore, a recommendation is
not needed.
The most common n-6 fatty acid, linoleic acid, is essential.
To prevent an essential fatty acid deficiency an intake of at
least 2·5 % of energy is recommended(36). On the basis of
aggregate data from randomised trials, case–control and
cohort studies, and long-term animal feeding experiments,
Harris et al.(37) concluded that an intake of at least 5 %
of energy from linoleic acid is needed to reduce CHD risk.
To prevent an essential fatty acid deficiency of the n-3 fatty
acid ALA, an intake of at least 0·5 % of energy is rec-
ommended(36). There is some but not yet convincing evidence
from prospective cohort studies that a high ALA intake is
associated with a lower CHD mortality risk(29). Upper limits
for the intake of both linoleic acid and ALA are not needed
for nutritionally adequate diets. Finally, there is convincing
evidence from prospective cohort studies and trials that an
intake of the n-3 fatty acids, EPA and DHA, of at least
250 mg/d is needed(33). There is no evidence that a higher
intake is needed for CHD prevention.
We propose to consume nutritionally adequate diets that
are low in saturated fat and as low as possible in trans-fat.
We raise concern about fabricated substitutes for trans-fat,
such as interesterified fats. Nutritionally adequate diets should
fulfil the requirements for the intake of n-6 and n-3 fatty acids.
No recommendation is needed for the intake of cis-MUFA.
Recommendations for fatty acid intake must be considered
in the context of whole diets. Natural experiments showed
that both traditional Mediterranean and Japanese diets were
associated with a low risk of CHD(38,39). The common feature
of these diets was that they were both low in saturated and
trans-fat, meat and dairy, and high in legumes, nuts and
vegetables. The traditional Mediterranean diet was high in
olive oil, whole grains and fruit, and moderate in fish while
the traditional Japanese diet was high in fish and rice(40).
This underscores that recommendations for fat intake must
be made within a food-based approach to CHD prevention(41,42).
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